

Supporting Information

Visible-Light-Induced Radical Trifluoromethylation/Cyclization of Alkynes: Synthesis of CF₃-Containing Dioxodibenzothiazepines

Xiaoyu Chen,^{a,*} Yang Geng,^b Pan Liu,^c Zhiyong Wu,^a Dapeng Zou,^c Yangjie Wu,^c Yusheng Wu^{c,d,*}

^a Flavors and Fragrance Engineering and Technology Research Center of Henan Province, College of Tobacco Science, Henan Agricultural University, Zhengzhou, 450046, People's Republic of China.

E-mail: xiaoyuchen@henau.edu.cn

^b Department of Pharmacy, Zhengzhou Railway Vocational and Technical College, Zhengzhou, 451460, People's Republic of China.

^c College of Chemistry, Green Catalysis Center, Henan Key Laboratory of Chemical Biology and Organic Chemistry, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.

^d TYK Medicines, Inc. Huzhou, 313000, People's Republic of China.

Tel.: (+1)-732-253-7326

Fax: (+1)-732-253-7327

E-mail: yusheng.wu@tykmedicines.com

Table of Contents


1. General Information.....	S2
2. Optimization of the reaction conditions.....	S2-S5
3. General procedure for the synthesis of trifluoromethylated dioxodibenzothiazepines.....	S5
4. Characterization data of products 3	S6-17
5. Mechanistic Experiments.....	S17-18
6. X-Ray crystallographic data of 3a	S18-S19
7. References.....	S19-20
8. Copies of ¹ H NMR, ¹³ C NMR, and ¹⁹ F NMR spectra.....	S20-60

1. General Information

All manipulations were performed in dried glass reaction tube equipped with a magnetic stir bar under air atmosphere. The solvents and reagents were purchased from commercial sources without further purification unless otherwise mentioned. Products were purified by flash chromatography on silica gel (100-200 mesh). All NMR spectra were obtained on Bruker AVANCE III systems using CDCl₃ or DMSO-*d*₆ as solvent, TMS as internal standard substance, at 400 MHz for ¹H NMR, 100 MHz for ¹³C NMR, and 376 MHz for ¹⁹F NMR. The chemical shifts (δ) are reported in ppm relative to tetramethylsilane. The multiplicities of signals are designated by the following abbreviations: s (singlet), d (doublet), t (triplet), q (quarter), m (multiplet), dd (doublet and doublet), td (triplet and doublet). The mass spectra were indicated by GC-MS (Thermo Fisher Scientific DSQ II). High-resolution mass spectrometry (HRMS) data were obtained on an Agilent Technologies 1290-6540 UHPLC/Accurate-Mass Quadrupole Time-of Flight (Q-TOF) LC/MS using ESI as ion source. Measured values are reported to 4 decimal places of the calculated value. X-ray analysis was performed with a single-crystal X-ray diffractometer (Gemini E). Melting points were measured with a SGW X-4A microscopic melting point apparatus and were uncorrected. Magnetic hot plate stirrer (MS-H-Pro⁺) was purchased from DLAB Scientific Co., Ltd. The material of the reaction vessel (Schlenk tubes) is borosilicate glass. *ortho*-sulfonamide phenylacetylenes **1** and TT-CF₃⁺OTf⁻ **2** were prepared according to the method in the literature.^{1,2}

2. Optimization of the reaction conditions

Table S1. Screening of Photocatalysts^a



Entry	Photocatalyst (5mol%)	Yield ^b (%)
1	-	28
2	Rose Bengal	32
3	Ru(bpy) ₃ Cl ₂ ·6H ₂ O	32
4	Eosin Y	40
5	Ir[dF(CF ₃) ₂ ppy] ₂ (dtbbpy)PF ₆	44
6	[Ir(dtbbpy)(ppy) ₂]PF ₆	45
7	<i>fac</i> -Ir(ppy) ₃	51
8	4CzIPN	60
9	Rhodaming 6G	23
10	[Mes-Acr ⁺] ⁺ ClO ₄ ⁻	26

^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv.), **2** (0.3 mmol, 1.5 equiv.), Photocatalyst (5 mol%), DMSO (2.0 mL), 30 °C, 6 h, air, 10 W blue LEDs. ^bIsolated yield.


Table S2. Screening of the Loading of Photocatalysts^a

1a + **2** $\xrightarrow[\text{DMSO, 6 h, 30 °C, 10 W blue LEDs}]{\text{4CzIPN}}$ **3a**

Entry	the volume of Catalyst	Yield ^b (%)
1	10 mol%	60
2	5 mol%	60
3	4 mol%	63
4	3 mol%	70
5	2 mol%	71
6	1 mol%	58

^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv.), **2** (0.3 mmol, 1.5 equiv.), 4CzIPN, DMSO (2.0 mL), 30 °C, 6 h, air, 10 W blue LEDs. ^bIsolated yield.


Table S3. Screening of Solvent^a



Entry	Solvent	Yield ^b (%)
1	CH ₃ CN (2 mL)	trace
2	DCE (2 mL)	26
3	Dioxane (2 mL)	32
4	THF (2 mL)	41
5	MeOH (2 mL)	44
6	DMAc (2 mL)	49
7	NMP (2 mL)	50
8	DMF (2 mL)	62
9	DMSO (2 mL)	71
10	DMSO (1 mL)	57
11	DMSO (3 mL)	65

^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv.), **2** (0.3 mmol, 1.5 equiv.), 4CzIPN (2 mol%), Solvent, 30 °C, 6 h, air, 10 W blue LEDs. ^bIsolated yield.

Table S4. Screening of Temperature and Time^a



Entry	Temperature (°C)	Time(h)	Yield ^b (%)
1	30	8	71
2	30	6	71
3	30	4	71
4	30	3	60

5	20	4	40
6	30	4	71
7	40	4	65

^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv.), **2** (0.3 mmol, 1.5 equiv.), 4CzIPN (2 mol%), DMSO (2.0 mL), Temperature, Time, air, 10 W blue LEDs. ^bIsolated yield.

Table S5. Screening of Light Source^a

1a + **2** $\xrightarrow[\text{Light source}]{4\text{CzIPN, DMSO, } 30\text{ }^{\circ}\text{C, 4 h}}$ **3a**

Entry	Light source	Yield ^b (%)
1	blue LEDs (10 W)	71
2	purple LEDs (10 W)	58
3	green LEDs (10 W)	55
4	white LEDs (10 W)	42
5	Dark	NR
6	blue LEDs (3 W)	60
7	blue LEDs (6 W)	64

^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv.), **2** (0.3 mmol, 1.5 equiv.), 4CzIPN (2 mol%), DMSO (2.0 mL), 30 °C, 4 h, air, light source. ^bIsolated yield.


Table S6. Screening of atmosphere^a

1a + **2** $\xrightarrow[10\text{ W blue LEDs}]{4\text{CzIPN, DMSO, } 30\text{ }^{\circ}\text{C, 4 h}}$ **3a**

Entry	atmosphere	Yield ^b (%)
1	O ₂	51
2	Ar	54


^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv.), **2** (0.3 mmol, 1.5 equiv.), 4CzIPN (2 mol%), DMSO (2.0 mL), 30 °C, 4 h, 10 W blue LEDs, atmosphere. ^bIsolated yield.

3. General procedure for the synthesis of trifluoromethylated dioxodibenzothiazepines




Experimental Procedure: A dried 25 mL Schlenk tube equipped with a magnetic stir bar was charged with *ortho*-sulfonamide phenylacetylenes **1** (0.20 mmol, 1.0 equiv), TT-CF₃⁺OTf⁻ **2** (0.30 mmol, 1.5 equiv), 4CzIPN (2 mol%) and DMSO (2.0 mL). The reaction mixture was then stirred at room temperature for 4 h under air atmosphere. The reaction mixture was washed with water and extracted with ethyl acetate three times. The combined organic layer was washed with saturated NaCl solution, dried with anhydrous Na₂SO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel (Petroleum ether/EtOAc) to afford desired products **3**.

4. Characterization data of products 3




(*E*)-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (**3a**)³

White solid, 71% yield (50.2 mg). M.p. = 127.6-128.9 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.81 (d, *J* = 8.1 Hz, 1 H), 7.53 (dd, *J* = 7.9 Hz, 1.3 Hz, 1 H), 7.45 (td, *J* = 7.6 Hz, 1.6 Hz, 1 H), 7.39-7.29 (m, 3 H), 7.24 (s, 1 H), 6.22 (q, *J* = 7.8 Hz, 1 H), 3.39 (s, 3H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, ppm): δ 150.2 (q, *J* = 5.7 Hz), 143.3, 137.9, 137.5, 136.3, 135.3, 131.3, 131.0, 130.0, 129.1, 129.0, 129.0 (q, *J* = 2.3 Hz), 128.3, 122.4 (q, *J* = 34.2 Hz), 122.1 (q, *J* = 269.9 Hz), 38.5, 21.4; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.19. MS (ESI) *m/z*: 353.1.




(E)-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3b)

White solid, 67% yield (45.5 mg). M.p. = 145.8-147.1 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.96-7.93 (m, 1 H), 7.56-7.53 (m, 3 H), 7.47-7.43 (m, 2 H), 7.38 (td, *J* = 7.5 Hz, 1.4 Hz, 1 H), 7.33-7.30 (m, 1 H), 6.22 (q, *J* = 7.8 Hz, 1 H), 3.41 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, ppm): δ 150.1 (q, *J* = 5.7 Hz), 140.9, 137.5, 136.2, 135.4, 132.5, 131.1, 130.7, 130.0, 129.2, 129.1 (q, *J* = 2.3 Hz), 128.7, 128.4, 122.8 (q, *J* = 34.2 Hz), 122.1 (q, *J* = 269.9 Hz), 38.6; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.24. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₃F₃NO₂S⁺ 340.0614; Found 340.0614.




(E)-2-(tert-butyl)-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3c)

White solid, 78% yield (61.7 mg). M.p. = 159.0-161.5 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.86 (d, *J* = 8.4 Hz, 1 H), 7.58-7.53 (m, 2 H), 7.46 (td, *J* = 7.5 Hz, 1.8 Hz, 1 H), 7.40-7.33 (m, 3 H), 6.20 (q, *J* = 7.8 Hz, 1 H), 3.40 (s, 3 H), 1.36 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃, ppm): δ 156.4, 150.8 (q, *J* = 5.5 Hz), 137.9, 137.7, 136.3, 135.2, 131.0, 130.1, 129.1, 129.1 (q, *J* = 2.4 Hz), 128.2, 128.1, 122.5 (q, *J* = 34.1 Hz), 122.2 (q, *J* = 269.9 Hz), 38.5, 35.3, 31.2; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.07. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₀H₂₁F₃NO₂S⁺ 396.1240; Found 396.1240.




(E)-2-methoxy-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3d)

White solid, 45% yield 33.4 mg). M.p. = 135.5-137.5 °C. **¹H NMR** (400 MHz, ClCD₃, ppm) δ 7.87 (d, *J* = 8.8 Hz, 1 H), 7.53 (dd, *J* = 7.8 Hz, 1.3 Hz, 1 H), 7.46 (td, *J* = 7.6, 1.6 Hz, 1 H), 7.37 (td, *J* = 7.5 Hz, 1.4 Hz, 1 H), 7.30 (d, *J* = 7.8 Hz, 1 H), 7.02 (dd, *J* = 8.8 Hz, 2.6 Hz, 1 H), 6.88 (d, *J* = 2.6 Hz, 1 H), 6.22 (q, *J* = 7.7 Hz, 1 H), 3.89 (s, 3 H), 3.38 (s, 3 H); **¹³C NMR** (100 MHz, CDCl₃, ppm): δ 162.2, 150.1 (q, *J* = 5.7 Hz), 137.3, 137.2, 136.4, 132.6, 131.0, 130.4, 130.0, 129.1, 129.0 (q, *J* = 2.2 Hz), 122.6 (q, *J* = 34.1 Hz), 122.1 (q, *J* = 270.0 Hz), 115.5, 114.0, 55.9, 38.5; **¹⁹F NMR** (376 MHz, ClCD₃, ppm) δ -56.27. **HRMS (ESI-TOF)** *m/z*: [M + H]⁺ Calcd for C₁₇H₁₅F₃NO₂S⁺ 370.0719; Found 370.0717.



(*E*)-2-fluoro-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3e)


White solid, 62% yield (44.3 mg). M.p. = 134.6-136.2 °C. **¹H NMR** (400 MHz, ClCD₃, ppm) δ 7.95 (dd, *J* = 8.8 Hz, 5.4 Hz, 1 H), 7.55-7.47 (m, 2 H), 7.40 (td, *J* = 7.6 Hz, 1.6 Hz, 1 H), 7.33-7.30 (m, 1 H), 7.24-7.21 (m, 1 H), 7.16 (dd, *J* = 9.0 Hz, 2.6 Hz, 1 H), 6.24 (q, *J* = 7.7 Hz, 1 H), 3.40 (s, 3 H); **¹³C NMR** (100 MHz, CDCl₃, ppm): δ 164.1 (d, *J* = 254.3 Hz), 149.0 (q, *J* = 6.2 Hz), 138.0 (d, *J* = 7.9 Hz), 137.0 (d, *J* = 3.7 Hz), 136.7, 136.1, 131.4, 131.2, 131.1, 130.1, 129.4, 129.2 (q, *J* = 2.5 Hz), 123.6 (q, *J* = 34.3 Hz), 121.9 (q, *J* = 270.0 Hz), 117.9 (d, *J* = 21.9 Hz), 115.6 (d, *J* = 23.5 Hz), 38.5, 35.3, 31.2; **¹⁹F NMR** (376 MHz, ClCD₃, ppm) δ -56.40, -105.36. **HRMS (ESI-TOF)** *m/z*: [M + H]⁺ Calcd for C₁₆H₁₂F₄NO₂S⁺ 358.0519; Found 358.0519.



(*E*)-2-chloro-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3f)


White solid, 55% yield (41.1 mg). M.p. = 120.3-122.1 °C. **¹H NMR** (400 MHz, ClCD₃, ppm) δ 7.88 (d, *J* = 8.5 Hz, 1 H), 7.55-7.47 (m, 3 H), 7.45 (d, *J* = 2.1 Hz, 1 H), 7.40 (td, *J* = 7.4 Hz, 1.5 Hz, 1 H), 7.32 (d, *J* = 7.7 Hz, 1 H), 6.25 (q, *J* = 7.6 Hz, 1 H), 3.39 (s, 3

H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 148.9 (q, $J = 5.6$ Hz), 139.3, 138.4, 136.9, 136.7, 136.0, 131.4, 130.7, 130.0, 129.9, 129.4, 129.2 (q, $J = 2.2$ Hz), 128.4, 123.6 (q, $J = 34.4$ Hz), 121.7 (q, $J = 270.1$ Hz), 38.6; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.39. **HRMS (ESI-TOF)** m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{12}\text{ClF}_3\text{NO}_2\text{S}^+$ 374.0224; Found 374.0222.



(E)-2-bromo-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (3g)


White solid, 60% yield (50.1 mg). M.p. = 155.4-156.9 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.80 (d, $J = 8.4$ Hz, 1 H), 7.67 (dd, $J = 8.5$ Hz, 2.0 Hz, 1 H), 7.61 (d, $J = 2.0$ Hz, 1 H), 7.55-7.47 (m, 2 H), 7.40 (td, $J = 7.4$ Hz, 1.5 Hz, 1 H), 7.31 (d, $J = 7.6$ Hz, 1 H), 6.25 (q, $J = 7.6$ Hz, 1 H), 3.39 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): 148.7 (q, $J = 5.5$ Hz), 139.9, 136.9, 136.7, 136.0, 133.6, 131.4, 131.3, 130.0, 129.9, 129.4, 1229.2 (q, $J = 2.3$ Hz), 126.7, 123.6 (q, $J = 34.4$ Hz), 121.9 (q, $J = 270.2$ Hz), 38.6; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.38. **HRMS (ESI-TOF)** m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{12}\text{BrF}_3\text{NO}_2\text{S}^+$ 417.9719; Found 417.9718.



(E)-6-methyl-11-(2,2,2-trifluoroethylidene)-2-(trifluoromethyl)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (3h)


White solid, 65% yield (53.0 mg). M.p. = 161.2-162.7 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 8.08 (d, $J = 8.3$ Hz, 1 H), 7.80 (dd, $J = 8.4$ Hz, 1.1 Hz, 1 H), 7.70 (s, 1 H), 7.57-7.49 (m, 2 H), 7.42 (td, $J = 7.4$ Hz, 1.5 Hz, 1 H), 7.35 (d, $J = 7.6$, 1 H), 6.30 (q, $J = 7.5$ Hz, 1 H), 3.42 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ , 148.9 (q, $J = 5.5$ Hz), 144.3, 136.7, 136.1, 135.8, 123.4 (q, $J = 33.3$ Hz), 131.5, 130.1, 129.6, 129.4, 129.3 (q, $J = 2.4$ Hz), 127.4 (q, $J = 3.6$ Hz), 125.7 (q, $J = 270.0$ Hz), 124.1 (q, $J = 34.5$ Hz), 121.8 (q, $J = 270.3$ Hz), 121.6, 38.7; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.41, -63.11. **HRMS (ESI-TOF)** m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{12}\text{F}_6\text{NO}_2\text{S}^+$ 408.0487; Found

408.0495.




methyl (*E*)-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine-2-carboxylate 5,5-dioxide (3i)

White solid, 57% yield (45.3 mg). M.p. = 198.7-199.6 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 8.16 (dd, J = 8.3, 1.7 Hz, 1 H), 8.11 (d, J = 1.7 Hz, 1 H), 8.02 (d, J = 8.2 Hz, 1 H), 7.55-7.47 (m, 2 H), 7.41 (td, J = 7.5 Hz, 1.4 Hz, 1 H), 7.33 (d, J = 7.6 Hz, 1 H), 6.30 (q, J = 7.6 Hz, 1 H), 3.99 (s, 3 H), 3.41 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 165.2, 149.2 (q, J = 5.3 Hz), 144.7, 137.0, 135.9, 135.7, 133.7, 131.4, 130.3, 130.1, 130.0, 129.5, 129.2 (q, J = 2.4 Hz), 128.9, 123.7 (q, J = 34.3 Hz), 121.9 (q, J = 270.3 Hz), 53.0, 38.7; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.33. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NO}_4\text{S}^+$ 398.0668; Found 398.0668.




(*E*)-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine-2-carbonitrile 5,5-dioxide (3j)

White solid, 50% yield (36.4 mg). M.p. = 207.6-208.9 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 8.05 (d, J = 8.2 Hz, 1 H), 7.81 (dd, J = 8.2 Hz, 1.6 Hz, 1 H), 7.77 (d, J = 1.7 Hz, 1 H), 7.56-7.50 (m, 2 H), 7.43 (td, J = 7.4 Hz, 1.8 Hz, 1 H), 7.34 (d, J = 7.7 Hz, 1 H), 6.29 (q, J = 7.5 Hz, 1 H), 3.41 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 148.2 (q, J = 5.3 Hz), 145.0, 136.4, 136.3, 135.7, 133.6, 132.3, 131.7, 130.1, 129.7, 129.5, 129.3 (q, J = 2.2 Hz), 124.5 (q, J = 34.8 Hz), 121.7 (q, J = 270.4 Hz), 116.7, 116.4, 38.8; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.48. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{12}\text{F}_3\text{N}_2\text{O}_2\text{S}^+$ 365.0566; Found 365.0574.




(E)-6-methyl-11-(2,2,2-trifluoroethylidene)-2-(trifluoromethoxy)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3k)

White solid, 55% yield (46.7 mg). M.p. = 110.7-111.9 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.99 (d, *J* = 8.7 Hz, 1 H), 7.56-7.48 (m, 2 H), 7.43-7.38 (m, 2 H), 7.35-7.29 (m, 2 H), 6.26 (q, *J* = 7.5 Hz, 1 H), 3.41 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, ppm): 151.3 (d, *J* = 1.8 Hz), 148.8 (q, *J* = 5.6 Hz), 139.3, 137.6, 136.6, 136.0, 131.5, 130.7, 130.1, 129.5, 129.3 (q, *J* = 2.4 Hz), 123.9 (q, *J* = 34.4 Hz), 122.3, 121.8 (q, *J* = 270.0 Hz), 120.5, 120.3 (q, *J* = 258.4 Hz), 38.7; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.43, -57.71. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₁₂F₆NO₃S⁺ 424.0437; Found 424.0440.



(E)-1-chloro-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3l)


White solid, 27% yield (20.2 mg). M.p. = 146.6-147.9 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.92 (d, *J* = 2.1 Hz, 1 H), 7.54-7.46 (m, 3 H), 7.42-7.38 (m, 2 H), 7.31 (d, *J* = 7.6 Hz, 1 H), 6.21 (q, *J* = 7.7 Hz, 1 H), 3.40 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, ppm): δ 149.0 (q, *J* = 5.4 Hz), 142.2, 137.0, 136.9, 135.8, 133.6, 132.6, 131.3, 130.1, 130.0, 129.4, 129.1 (q, *J* = 2.1 Hz), 128.4, 123.2 (q, *J* = 34.3 Hz), 121.9 (q, *J* = 270.0 Hz), 38.7; ¹⁹F NMR (376 MHz, ClC D₃, ppm) δ -56.33. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₂ClF₃NO₂S⁺ 374.0224; Found 374.0222.



(E)-3-chloro-6-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3l')


White solid, 27% yield (20.2 mg). M.p. = 162.7-164.3 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.85 (dd, *J* = 7.9 Hz, *J* = 1.0 Hz, 1 H), 7.66 (dd, *J* = 8.0 Hz, *J* = 1.1 Hz, 1 H), 7.48-7.41 (m, 4 H), 7.38-7.34 (m, 1 H), 6.16 (q, *J* = 7.8 Hz, 1 H), 3.35 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, ppm): δ 143.3 (q, *J* = 5.8 Hz), 141.9, 137.2, 136.9, 134.1, 133.0, 132.2, 131.1, 130.3, 129.4 (q, *J* = 2.6 Hz), 128.2, 127.9, 126.3, 125.5 (q, *J* = 33.9 Hz), 122.0 (q, *J* = 270.3 Hz), 39.3; ¹⁹F NMR (376 MHz, ClC D₃, ppm) δ -57.40. HRMS

(ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{16}H_{12}ClF_3NO_2S^+$ 374.0224; Found 374.0222.




(E)-1,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (3m)

White solid, 28% yield (19.8 mg). M.p. = 181.6-183.1 °C. 1H NMR (400 MHz, $ClCD_3$, ppm) δ 7.78 (d, J = 7.8 Hz, 1 H), 7.48-7.36 (m, 5 H), 7.32-7.28 (m, 1 H), 5.91 (q, J = 8.0 Hz, 1 H), 3.30 (s, 3 H), 2.51 (s, 3 H); ^{13}C NMR (100 MHz, $CDCl_3$, ppm): δ 146.7 (q, J = 5.8 Hz), 142.2, 139.4, 138.3, 135.3, 134.1, 132.7, 130.8, 129.2 (q, J = 2.7 Hz), 128.9, 127.1, 127.0, 125.1, 123.1 (q, J = 33.8 Hz), 122.2 (q, J = 270.0 Hz), 39.4, 20.7; ^{19}F NMR (376 MHz, $ClC D_3$, ppm) δ -57.02. **HRMS (ESI-TOF)** m/z : $[M + H]^+$ Calcd for $C_{17}H_{15}F_3NO_2S^+$ 354.0770; Found 354.0768.




(E)-3,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (3m')

White solid, 28% yield (19.8 mg). M.p. = 196.1-197.9 °C. 1H NMR (400 MHz, $ClCD_3$, ppm) δ 7.75 (s, 1 H), 7.53 (dd, J = 7.8 Hz, J = 1.0 Hz, 1 H), 7.47-7.43 (m, 1 H), 7.39-7.29 (m, 4 H), 6.19 (q, J = 7.8 Hz, 1 H), 3.40 (s, 3 H), 2.39 (s, 3 H); ^{13}C NMR (100 MHz, $CDCl_3$, ppm): δ 150.0 (q, J = 5.5 Hz), 141.4, 140.5, 137.7, 136.1, 133.3, 132.6, 130.9, 130.1, 129.2, 129.0 (q, J = 2.5 Hz), 128.6, 128.5, 127.9, 126.3, 122.3 (q, J = 34.0 Hz), 122.1 (q, J = 269.8 Hz), 38.6, 21.1; ^{19}F NMR (376 MHz, $ClC D_3$, ppm) δ -56.16. **HRMS (ESI-TOF)** m/z : $[M + H]^+$ Calcd for $C_{17}H_{15}F_3NO_2S^+$ 354.0770; Found 354.0768.




(E)-2,6,9-trimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (3o)

White solid, 59% yield (43.5 mg). M.p. = 123.6-125.3 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.81 (d, J = 8.1 Hz, 1 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.33 (dd, J = 8.0 Hz, 0.8 Hz, 1 H), 7.25-7.21 (m, 1 H), 7.21 (d, J = 1.8 Hz, 1 H), 7.09 (s, 1 H), 6.19 (q, J = 7.8 Hz, 1 H), 3.37 (s, 3 H), 2.43 (s, 3 H), 2.35 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 150.4 (q, J = 5.7 Hz), 143.2, 139.4, 138.0, 137.4, 135.5, 133.5, 131.6, 131.3, 129.8, 129.4 (q, J = 2.2 Hz), 129.0, 128.5, 122.2 (q, J = 34.1 Hz), 122.2 (q, J = 269.9 Hz), 38.6, 21.5, 21.3; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.21. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{17}\text{F}_3\text{NO}_2\text{S}^+$ 368.0927; Found 368.0926.




(*E*)-9-methoxy-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3p)

White solid, 53% yield (40.9 mg). M.p. = 139.7-141.2 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.80 (d, J = 8.1 Hz, 1 H), 7.43 (d, J = 2.2 Hz, 1 H), 7.34 (dd, J = 8.1 Hz, 0.8 Hz, 1 H), 8.23 (s, 1 H), 6.93 (dd, J = 8.7 Hz, 2.9 Hz, 1 H), 6.79 (d, J = 2.1 Hz, 1 H), 6.21 (q, J = 7.8 Hz, 1 H), 3.78 (s, 3 H), 3.36 (s, 3 H), 2.43 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): 159.7, 150.1 (q, J = 5.3 Hz), 143.1, 138.8, 138.1, 135.1, 131.4, 129.1, 128.5, 122.1 (q, J = 270.0 Hz), 122.4 (q, J = 34.2 Hz), 116.0, 114.1 (q, J = 2.5 Hz), 55.7, 38.7, 21.4; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.13. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{17}\text{F}_3\text{NO}_3\text{S}^+$ 384.0876; Found 384.0879.




(*E*)-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine-9-carbonitrile 5,5-dioxide (3q)

White solid, 73% yield (55.5 mg). M.p. = 168.4-170.1 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.82-7.74 (m, 2 H), 7.63-7.60 (m, 2 H), 7.39 (d, J = 8.0 Hz, 1 H), 6.25 (q, J = 7.6 Hz, 1 H), 3.39 (s, 3 H), 2.46 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): 147.9 (q, J = 5.4 Hz), 144.1, 141.1, 137.5, 137.1, 134.6, 134.5, 134.2, 132.9 (q, J = 2.7 Hz), 131.7, 130.3, 129.2, 128.0, 123.7 (q, J = 34.5 Hz), 121.8 (q, J = 270.0 Hz), 117.4, 112.8, 38.3, 21.5; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.22. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_2\text{S}^+$ 379.0723; Found 379.0727




(*E*)-9-fluoro-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3r)

White solid, 70% yield (52.0 mg). M.p. = 150.8-152.2 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.81 (d, J = 8.1 Hz, 1 H), 7.51 (dd, J = 8.7 Hz, 5.0 Hz, 1 H), 7.36 (dd, J = 8.0 Hz, 0.9 Hz, 1 H), 7.22 (s, 1 H), 7.14 (td, J = 8.2 Hz, 2.9 Hz, 1 H), 7.01 (dd, J = 7.9 Hz, 2.4 Hz, 1 H), 6.23 (q, J = 7.8 Hz, 1 H), 3.37 (s, 3 H), 2.44 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 162.2 (d, J = 249.7 Hz), 148.8 (q, J = 4.1 Hz), 143.5, 139.6 (d, J = 9.0 Hz), 137.9, 134.6, 132.3, 132.2, 131.7, 129.2, 128.5, 123.0 (d, J = 34.3 Hz), 121.9 (q, J = 270.2 Hz), 117.9 (d, J = 22.6 Hz), 116.1 (dd, J = 24.3 Hz, 2.5 Hz), 38.6, 21.5; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.29, -110.68. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{14}\text{F}_4\text{NO}_2\text{S}^+$ 372.0676; Found 372.0674.




(*E*)-9-chloro-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3s)

White solid, 69% yield (53.4 mg). M.p. = 147.0-148.5 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.81 (d, J = 8.1 Hz, 1 H), 7.47-7.40 (m, 2 H), 7.36 (dd, J = 8.1 Hz, 0.9 Hz, 1 H), 7.30 (d, J = 0.9 Hz, 1 H), 7.22 (s, 1 H), 6.23 (q, J = 7.7 Hz, 1 H), 3.37 (s, 3 H), 2.44 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 148.7 (q, J = 5.7 Hz), 143.5, 139.0, 137.8, 135.0, 134.9, 134.7, 131.6, 131.4, 131.1, 129.1, 128.9 (q, J = 2.3 Hz), 128.4, 123.1 (q, J = 32.3 Hz), 122.0 (q, J = 270.0 Hz), 38.5, 21.5; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.27. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{14}\text{ClF}_3\text{NO}_2\text{S}^+$ 388.0380; Found 388.0382.




(E)-9-bromo-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3t)

White solid, 62% yield (53.5 mg). M.p. = 163.2-164.8 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.81 (d, *J* = 8.1 Hz, 1 H), 7.58 (dd, *J* = 8.4 Hz, 2.3 Hz, 1 H), 7.45 (d, *J* = 1.0 Hz, 1 H), 7.39 (d, *J* = 8.4 Hz, 1 H), 7.36 (dd, *J* = 8.1 Hz, 0.9 Hz, 1 H), 7.22 (s, 1 H), 6.23 (q, *J* = 7.7 Hz, 1 H), 3.37 (s, 3H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃, ppm): 148.7 (q, *J* = 5.7 Hz), 143.6, 139.2, 137.8, 135.5, 134.7, 134.1, 131.8 (q, *J* = 2.6 Hz), 131.63, 131.62, 129.1, 128.4, 123.0 (q, *J* = 34.2 Hz), 122.9, 122.0 (q, *J* = 270.2 Hz), 38.4, 21.5; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.26. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₁₄BrF₃NO₂S⁺ 431.9875; Found 431.9872.



(E)-8-fluoro-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3u)


White solid, 71% yield (52.8 mg). M.p. = 134.8-136.3 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.81 (d, *J* = 8.1 Hz, 1 H), 7.36 (d, *J* = 8.1 Hz, 1 H), 7.28 (dd, *J* = 8.3 Hz, 6.6 Hz, 1 H), 7.25-7.23 (m, 2 H), 7.08 (td, *J* = 8.3 Hz, 2.5 Hz, 1 H), 6.21 (q, *J* = 7.8 Hz, 1 H), 3.37 (s, 3 H), 2.44 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, ppm): δ 163.5 (d, *J* = 250.6 Hz), 149.3 (q, *J* = 5.4 Hz), 143.6, 138.2 (d, *J* = 10.2 Hz), 137.6, 135.2, 133.2 (d, *J* = 3.4 Hz), 131.5 130.5 (dd, *J* = 9.2 Hz, 2.5 Hz), 129.1, 128.3, 123.0 (q, *J* = 34.0 Hz), 122.1 (q, *J* = 270.0 Hz), 117.2 (d, *J* = 22.5 Hz), 116.4 (d, *J* = 21.6 Hz), 38.4, 21.5; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.24, -108.90. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₁₄F₄NO₂S⁺ 372.0676; Found 372.0678.



(E)-8-chloro-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3v)


White solid, 69% yield (53.5 mg). M.p. = 176.1-177.7 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.81 (d, *J* = 8.1 Hz, 1 H), 7.52 (d, *J* = 2.0 Hz, 1 H), 7.37-7.34 (m, 2 H), 7.25-

7.23 (m, 2 H), 6.22 (q, $J = 7.8$ Hz, 1 H), 3.37 (s, 3 H), 2.44 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): δ 149.2 (q, $J = 5.6$ Hz), 143.6, 137.7, 136.3, 135.7, 131.5, 130.2, 130.0 (q, $J = 2.6$ Hz), 129.4, 129.1, 128.3, 123.0 (q, $J = 34.2$ Hz), 122.0 (q, $J = 270.0$ Hz), 38.5, 21.5; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.20. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{14}\text{ClF}_3\text{NO}_2\text{S}^+$ 388.0380; Found 388.0382.




(*E*)-8-bromo-2,6-dimethyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3w)

White solid, 73% yield (63.0 mg). M.p. = 186.0-187.3 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.81 (d, $J = 8.1$ Hz, 1 H), 7.68 (d, $J = 1.9$ Hz, 1 H), 7.50 (dd, $J = 8.2$ Hz, 1.9 Hz, 1 H), 7.36 (dd, $J = 8.1$ Hz, 0.9 Hz, 1 H), 7.22 (s, 1 H), 7.18 (d, $J = 8.2$ Hz, 1 H), 6.22 (q, $J = 7.7$ Hz, 1 H), 3.37 (s, 3 H), 2.44 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): 149.2 (q, $J = 5.3$ Hz), 143.6, 137.7, 137.6, 136.2, 134.8, 133.1, 132.3, 131.5, 130.2 (q, $J = 2.3$ Hz), 129.1, 128.3, 124.1, 123.0 (q, $J = 34.2$ Hz), 122.0 (q, $J = 269.9$ Hz), 38.5, 21.5; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.18. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{14}\text{BrF}_3\text{NO}_2\text{S}^+$ 431.9875; Found 431.9874.




(*E*)-6-isopropyl-2-methyl-11-(2,2,2-trifluoroethylidene)-6,11-dihydrodibenzo[*c,f*][1,2]thiazepine 5,5-dioxide (3x)³

White solid, 79% yield (60.2 mg). M.p. = 145.1-146.9 °C. ^1H NMR (400 MHz, ClCD_3 , ppm) δ 7.84 (d, $J = 8.1$ Hz, 1 H), 7.53 (dd, $J = 7.9$ Hz, 1.3 Hz, 1H), 7.46 (td, $J = 7.6$ Hz, 1.7 Hz, 1 H), 7.38 (td, $J = 7.5$, Hz 1.3 Hz, 1 H), 7.34-7.30 (m, 2 H), 7.24 (s, 1 H), 6.17 (q, $J = 8.0$ Hz, 1H), 4.64-4.57 (m, 1 H), 2.42 (s, 3 H), 1.49 (like s, 3 H), 1.19 (like s, 3 H); ^{13}C NMR (100 MHz, CDCl_3 , ppm): 150.2 (q, $J = 5.5$ Hz), 142.9, 139.3, 138.9, 135.4, 132.9, 131.9, 131.3, 130.4, 129.5, 129.1, 129.1 (q, $J = 4.9$ Hz), 127.8, 122.2 (q, $J = 269.7$ Hz), 121.3 (q, $J = 34.3$ Hz), 54.2, 24.2, 21.6, 21.4; ^{19}F NMR (376 MHz, ClCD_3 , ppm) δ -56.34. MS (ESI) m/z : 381.1.



(*E*)-(2-methyl-5,5-dioxido-11-(2,2,2-trifluoroethylidene)dibenzo[*c,f*][1,2]thiazepin-6(11H)-yl)(phenyl)methanone (3y)³


White solid, 70% yield (62.1 mg). M.p. = 179.5-181.0 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.89 (d, *J* = 8.1 Hz, 1H), 7.82 (dd, *J* = 8.0 Hz, 1.2 Hz, 1 H), 7.75-7.73 (m, 2 H), 7.52-7.38 (m, 4 H), 7.36-7.31 (m, 4 H), 7.23 (d, *J* = 7.7 Hz, 1 H), 6.26 (q, *J* = 7.7 Hz, 1 H), 2.47 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, ppm): 169.4, 147.9 (q, *J* = 5.4 Hz), 144.2, 137.5, 137.3, 134.6, 133.1, 132.9, 132.8, 132.6, 131.9, 130.7, 130.4, 130.1, 130.0, 129.0 (q, *J* = 2.3 Hz), 128.2, 127.7, 123.9 (q, *J* = 34.2 Hz), 121.6 (q, *J* = 270.2 Hz), 21.6; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.56. MS (ESI) *m/z*: [M + H]⁺ 444.1.




tert-butyl (*E*)-2-methyl-11-(2,2,2-trifluoroethylidene)dibenzo[*c,f*][1,2]thiazepine-6(11H)-carboxylate 5,5-dioxide (3z)³

White solid, 70% yield (61.5 mg). M.p. = 125.8-127.3 °C. ¹H NMR (400 MHz, ClCD₃, ppm) δ 7.89 (d, *J* = 8.1 Hz, 1 H), 7.55 (dd, *J* = 7.9 Hz, 1.4 Hz, 1 H), 7.49 (td, *J* = 7.6 Hz, 1.6 Hz, 1 H), 7.43-7.38 (m, 2 H), 7.34-7.33 (m, 2 H), 6.21 (q, *J* = 7.7 Hz, 1 H), 2.46 (s, 3 H), 1.39 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃, ppm): 149.5, 148.4 (q, *J* = 5.7 Hz), 144.1, 137.2, 136.1, 134.6, 133.2, 131.6, 131.1, 130.7, 130.3, 129.6, 128.8 (q, *J* = 2.6 Hz), 127.6, 124.1 (q, *J* = 34.3 Hz), 121.8 (q, *J* = 270.2 Hz), 85.4, 27.6, 21.5; ¹⁹F NMR (376 MHz, ClCD₃, ppm) δ -56.08. MS (ESI) *m/z*: [M + H]⁺ 440.1.

5. Mechanistic Experiments



(a) A dried 25 mL Schlenk tube equipped with a magnetic stir bar was charged with *N*-(2-ethynylphenyl)-*N*,4-dimethylbenzenesulfonamide **1a** (0.20 mmol, 1.0 equiv), TT-CF₃⁺OTf⁻ **2** (0.30 mmol, 1.5 equiv), 4CzIPN (2 mol%), TEMPO (0.4 mmol, 2.0 equiv) and DMSO (2.0 mL). The reaction mixture was then stirred at room temperature for 4 h under air atmosphere. The reaction mixture was washed with water and extracted with ethyl acetate three times. The combined organic layer was washed with saturated NaCl solution, dried with anhydrous Na₂SO₄ and filtered. The filtrate was concentrated in vacuo. The analysis of crude mixture showed that the yield of **3a** was completely inhibited.



(b) A dried 25 mL Schlenk tube equipped with a magnetic stir bar was charged with *N*-(2-ethynylphenyl)-*N*,4-dimethylbenzenesulfonamide **1a** (0.20 mmol, 1.0 equiv), TT-CF₃⁺OTf⁻ **2** (0.30 mmol, 1.5 equiv), 4CzIPN (2 mol%), 1, 1-diphenylethylene (0.4 mmol, 2.0 equiv) and DMSO (2.0 mL). The reaction mixture was then stirred at room temperature for 4 h under air atmosphere. The reaction mixture was washed with water and extracted with ethyl acetate three times. The combined organic layer was washed with saturated NaCl solution, dried with anhydrous Na₂SO₄ and filtered. The filtrate was concentrated in vacuo. The analysis of crude mixture showed that the yield of **3a** was totally suppressed. The expected adduct **4** was observed by GC-MS as following: **GC-MS** (*m/z*, relative intensity): 248 (*M*⁺, 90), 178 (100), 165 (100), 151 (30), 89 (43), 76 (37). The data for the adduct **4** were in accordance with the ones previously reported in the literature.⁴




Figure S1. GC-MS (m/z) of adduct **4**

6. X-ray crystallographic data of **3a**

The product **3a** was recrystallized from petroleum ether/EtOAc. Further information can be found in the CIF file. This crystal was deposited in the Cambridge Crystallographic Data Centre and assigned as CCDC **2425399**.




Figure S2. X-ray crystal structure of **3a** (CDCC: 2425399)

Table S7. Crystal data and structure refinement for **3a**.

Identification code	3a
Empirical formula	C ₁₇ H ₁₄ F ₃ NO ₂ S
Formula weight	353.35
Temperature/K	150

Crystal system	triclinic
Space group	P-1
a/Å	7.8410 (4)
b/Å	9.9763 (5)
c/Å	10.8160 (6)
$\alpha/^\circ$	90.279 (6)
$\beta/^\circ$	101.789 (5)
$\gamma/^\circ$	106.790 (5)
Volume/Å ³	791.07 (8)
Z	2
$\rho_{\text{calc}}/\text{cm}^3$	1.483
μ/mm^{-1}	0.247
F(000)	364.0
Crystal size/mm ³	0.16 × 0.11 × 0.1
Radiation	Mo K α (λ = 0.71073)
2 Θ range for data collection/ $^\circ$	5.556 to 52.742

7. References

- [1] (a) Xiao Q, Lu M J, Deng Y L, et al. Photoinduced Radical Cascade Cyclization: A Metal-Free Approach to Access Difluoroalkylated Dioxodibenzothiazepines. *Org. Lett.* **2021**, 23, 9303-9308. (b) Zheng X Y, Shen Q T, Yin C L, et al. Photoinduced Three-Component Difluoroamidofluoromethylation/Bicyclization: Regioselectivity Synthesis of Seven-Membered Dibenzosultams. *Adv. Synth. Catal.* **2022**, 364, 1750-1756. (c) Chen X Y, Geng Y, Liu B, et al. Photochemical difluoromethylation of alkynes: synthesis of CF₂H-substituted seven-membered dioxodibenzothiazepines and dibenzazepines. *Org. Chem. Front.*, **2023**, 10, 1968-1974. (d) Guo C Y, Li L J, Yan Q Q, et al. Photoinduced Tandem Cyanomethylation/Cyclization of Unsaturated Compounds: Access to Cyanomethylated 7- or 5-Membered N-Heterocycles. *J. Org. Chem.* **2023**, 88, 12141-12149. (e) Tian Y F, Zheng L P, Guo D Y, et al. Photo-Induced Difluoroethylation or Monofluoromethyl Sulfonylation of 2-Amino Aryl Ethynes to Access Diverse Seven-Membered N-Heterocycles. *Eur. J. Org. Chem.* **2024**, 27, 1-4.
- [2] Jia H, Häring A P, Berger F, et al. Trifluoromethyl Thianthrenium Triflate: A Readily Available Trifluoromethylating Reagent with Formal CF₃⁺, CF₃[•], and CF₃⁻ Reactivity. *J. Am. Chem. Soc.*, **2021**, 143, 7623-7628.
- [3] Zhang, Z.-Q.; Xu, Y.-H.; Dai, J.-C.; Li, Y.; Sheng, J.; Wang, X.-S. Copper-Catalyzed Trifluoromethylation/Cyclization of Alkynes for Synthesis of Dioxodibenzothiazepines. *Org. Lett.* **2021**, 23, 2194-2198.
- [4] (a) Xu, C., Huang, W., Zhang, R., Gao, C., Li, Y., Wang, M. Trifluoromethylations of Alkenes Using PhICl₃ as Bifunctional Reagent. *J. Org. Chem.* **2019**, 84, 14209-14216. (b) Ma, J. J., Yi, W. B., Lu, G. P., Cai, C. Decarboxylative and Denitrative Trifluoromethylation for the Synthesis of Cvinyl-CF₃ Compounds with Togni (II) Reagent. *Adv. Synth. Catal.*, **2015**, 357, 3447-3452.

8. Copies of ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra




Figure S3. ¹H NMR (400 MHz, CDCl₃) of compound **3a**




Figure S4. ¹³C NMR (100 MHz, CDCl₃) of compound **3a**




Figure S5. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3a**




Figure S6. ¹H NMR (400 MHz, CDCl₃) of compound **3b**




Figure S7. ¹³C NMR (100 MHz, CDCl₃) of compound **3b**




Figure S8. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3b**




Figure S9. ¹H NMR (400 MHz, CDCl₃) of compound 3c




Figure S10. ¹³C NMR (100 MHz, CDCl₃) of compound 3c




Figure S11. ^{19}F NMR (376 MHz, CDCl_3) of compound **3c**




Figure S12. ^1H NMR (400 MHz, CDCl_3) of compound **3d**




Figure S13. ¹³C NMR (100 MHz, CDCl₃) of compound **3d**




Figure S14. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3d**




Figure S15. ¹H NMR (400 MHz, CDCl₃) of compound 3e




Figure S16. ¹³C NMR (100 MHz, CDCl₃) of compound 3e




Figure S17. ^{19}F NMR (376 MHz, CDCl_3) of compound **3e**




Figure S18. ^1H NMR (400 MHz, CDCl_3) of compound **3f**




Figure S19. ^{13}C NMR (100 MHz, CDCl_3) of compound **3f**




Figure S20. ^{19}F NMR (376 MHz, CDCl_3) of compound **3f**




Figure S21. ¹H NMR (400 MHz, CDCl₃) of compound **3g**




Figure S22. ¹³C NMR (100 MHz, CDCl₃) of compound **3g**




Figure S23. ^{19}F NMR (376 MHz, CDCl_3) of compound **3g**




Figure S24. ^1H NMR (400 MHz, CDCl_3) of compound **3h**




Figure S25. ¹³C NMR (100 MHz, CDCl₃) of compound **3h**




Figure S26. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3h**




Figure S27. ¹H NMR (400 MHz, CDCl₃) of compound **3i**




Figure S28. ¹³C NMR (100 MHz, CDCl₃) of compound **3i**




Figure S29. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3i**




Figure S30. ¹H NMR (400 MHz, CDCl₃) of compound **3j**




Figure S31. ¹³C NMR (100 MHz, CDCl₃) of compound **3j**




Figure S32. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3j**




Figure S33. ¹H NMR (400 MHz, CDCl₃) of compound **3k**




Figure S34. ¹³C NMR (100 MHz, CDCl₃) of compound **3k**




Figure S35. ^{19}F NMR (376 MHz, CDCl_3) of compound **3k**




Figure S36. ^1H NMR (400 MHz, CDCl_3) of compound **3l**




Figure S37. ^{13}C NMR (100 MHz, CDCl_3) of compound **31**




Figure S38. ^{19}F NMR (376 MHz, CDCl_3) of compound **31**




Figure S39. ¹H NMR (400 MHz, CDCl₃) of compound 31'




Figure S40. ¹³C NMR (100 MHz, CDCl₃) of compound 31'




Figure S41. ^{19}F NMR (376 MHz, CDCl_3) of compound **3l'**




Figure S42. ^1H NMR (400 MHz, CDCl_3) of compound **3m**




Figure S43. ¹³C NMR (100 MHz, CDCl₃) of compound **3m**




Figure S44. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3m**




Figure S45. ¹H NMR (400 MHz, CDCl₃) of compound **3m'**




Figure S46. ¹³C NMR (100 MHz, CDCl₃) of compound **3m'**




Figure S47. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3m'**




Figure S48. ¹H NMR (400 MHz, CDCl₃) of compound **3o**




Figure S49. ¹³C NMR (100 MHz, CDCl₃) of compound **3o**




Figure S50. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3o**




Figure S51. ¹H NMR (400 MHz, CDCl₃) of compound **3p**




Figure S52. ¹³C NMR (100 MHz, CDCl₃) of compound **3p**




Figure S53. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3p**




Figure S54. ¹H NMR (400 MHz, CDCl₃) of compound **3q**




Figure S55. ¹³C NMR (100 MHz, CDCl₃) of compound **3q**




Figure S56. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3q**




Figure S57. ¹H NMR (400 MHz, CDCl₃) of compound 3r




Figure S58. ¹³C NMR (100 MHz, CDCl₃) of compound 3r




Figure S59. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3r**




Figure S60. ¹H NMR (400 MHz, CDCl₃) of compound **3s**




Figure S61. ¹³C NMR (100 MHz, CDCl₃) of compound **3s**




Figure S62. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3s**




Figure S63. ¹H NMR (400 MHz, CDCl₃) of compound 3t




Figure S64. ¹³C NMR (100 MHz, CDCl₃) of compound 3t




Figure S65. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3t**




Figure S66. ¹H NMR (400 MHz, CDCl₃) of compound **3u**




Figure S67. ¹³C NMR (100 MHz, CDCl₃) of compound **3u**




Figure S68. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3u**




Figure S69. ¹H NMR (400 MHz, CDCl₃) of compound **3v**




Figure S70. ¹³C NMR (100 MHz, CDCl₃) of compound **3v**




Figure S71. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3v**




Figure S72. ¹H NMR (400 MHz, CDCl₃) of compound **3w**




Figure S73. ¹³C NMR (100 MHz, CDCl₃) of compound **3w**




Figure S74. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3w**




Figure S75. ¹H NMR (400 MHz, CDCl₃) of compound **3x**




Figure S76. ¹³C NMR (100 MHz, CDCl₃) of compound **3x**




Figure S77. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3x**




Figure S78. ¹H NMR (400 MHz, CDCl₃) of compound **3y**




Figure S79. ¹³C NMR (100 MHz, CDCl₃) of compound **3y**




Figure S80. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3y**




Figure S81. ¹H NMR (400 MHz, CDCl₃) of compound **3z**




Figure S82. ¹³C NMR (100 MHz, CDCl₃) of compound **3z**




Figure S83. ¹⁹F NMR (376 MHz, CDCl₃) of compound **3z**